Cadrenal Therapeutics Shares Are Trading Higher After the Company Received FDA Orphan Drug Designation for Tecarfarin for the Prevention of Thromboembolism and Thrombosis in Patients With an Implanted Mechanical Circulatory Support Device
Cadrenal Therapeutics的股價走高，此前該公司獲得美國食品藥品管理局的替卡法林孤兒藥認定，用於預防植入機械循環支持裝置患者的血栓栓塞和血栓形成